About US
Contact us
>>Back
Shionogi to take 10pc stake in GSK HIV drug
- Publisher：
- Publication：2012/11/2
Japanese pharmaceutical group Shionogi is to receive a ten per cent stake in ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK) and Pfizer.
Under the terms of the deal, ViiV will acquire exclusive global rights to HIV treatments developed with Shionogi, including the experimental integrase inhibitor dolutegravir.
GSK will own 76.5 per cent of ViiV and Pfizer will receive a 13.5 per cent stake, with GSK entitled to an extra 1.8 per cent if dolutegravir achieves marketing approval in both the US and Europe.
In addition to its ten per cent stake, Shionogi will receive ongoing royalties on net sales of any drugs resulting from the relationship with ViiV Healthcare and will be entitled to ongoing dividends.
Dr Isao Teshirogi, president and chief executive officer of Shionogi & Co, commented: "The new deal perfectly aligns with the strategic goals and capabilities of both companies.
"Shionogi are able to secure a continued revenue stream from the integrase inhibitor portfolio as well as a stake in ViiV Healthcare itself, and will be able to contribute to the future direction of these compounds, which we know very well and continue to be excited about."